CORONA VIRUS DISEASE-19 PANDEMIC - THERAPEUTICS AND NOVEL DEVELOPMENT

NIRAJ KHATRI SAPKOTA; ARUN KOIRALA; RAM LOCHAN YADAV; SAMEER TIMILSINA; PUJAN BHUSAL

doi:10.22159/ijs.2021.v9i5.39721

Authors

NIRAJ KHATRI SAPKOTA Department of Physiology, Chitwan Medical College, Chitwan, Bharatpur, Nepal.
ARUN KOIRALA Department of Public Health, School of Public Health, Chitwan Medical College, Chitwan, Bharatpur, Nepal.
RAM LOCHAN YADAV Department of Physiology, Chitwan Medical College, Chitwan, Bharatpur, Nepal.
SAMEER TIMILSINA Department of Physiology, Chitwan Medical College, Chitwan, Bharatpur, Nepal.
PUJAN BHUSAL Department of Physiology, Chitwan Medical College, Chitwan, Bharatpur, Nepal.

DOI:

https://doi.org/10.22159/ijs.2021.v9i5.39721

Keywords:

Coronavirus disease-19, Drugs, Pandemic

Abstract

Every individual must follow the slogan of front line worker as “we stay at work for you, you stay at home,” This means to protect the healthcare worker who are working in the frontline to save life of the corona virus disease (COVID)-19 patient of the different phases, other should stay home safe and secured; however, if we could not protect them than the matter will be serious to everyone to control the situation of this pandemic and many life can be lost. Thus, it is suggested to the young asymptmatic people to remain quarantine and isolated until the incubation period be over, it could be as long as 41 days or as short as 6 days but average time necessary is 14 days. There are no drugs or other therapeutics presently working to knock out COVID-19 pandemic. However, drugs employed in the treatment of hospitalized patient are on the basis of previous exposure of congruent strain of virus; in addition, supportive care management such as supplemental oxygen and mechanical ventilation procedure is highly being used to the critical patient. This review highlights step to step treatment plan, employed therapeutics, mechanism, efficacy, and new development of the clinical trial results if any.

References

Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf 2017;16:411-9.

Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology. Nat Rev Rheumatol 2020;16:155-66.

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69.

Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020;12:8.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.

Dimitrov DS. The secret life of ACE2 as a receptor for the SARS virus. Cell 2003;115:652-3.

Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A 2004;101:4240-5.

Yeung KS, Yamanaka GA, Meanwell NA. Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. Med Res Rev 2006;26:414-33.

Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72-3.

Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV); 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04303507 [Last accessed on 2020 Mar 11].

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:732-9.

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;20:105949.

Mulangu S, Dodd LE, Davey RT Jr., Mbaya OT, Proschan M, Mukadi D, et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med 2019;381:2293-303.

de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020;117:6771-6.

Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Communs 2020;11:222.

Cao B. Mild/moderate 2019-nCoV Remdesivir RCT Full Text View; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04252664

Cao B. Severe 2019-nCoV remdesivir RCT Full Text View; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04257656

Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-6.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan J, et al. A Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382:1787-99.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, et al. Advances in respiratory virus therapeutics a meeting report from the 6th isirv Antiviral Group conference. Antiviral Res 2019;167:45-67.

Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD. Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 2015;11:1781-94.

Ben-Chetrit E. Colchicine. In: Hashkes P, Laxer R, Simon A, editors. Textbook of Autoinflammation. Cham: Springer; 2019. p. 729-49.

Leung YY, Yao Hui LL, Kraus VB. Colchicine--Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 2015;45:341-50.

Kiraz S, Ertenli I, Arici M, Calgüneri M, Haznedaroglu I, Celik I, et al. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol 1998;16:721-4.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.

Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi 2020;36:E005.

Hoffman E, Rahat MA, Feld J, Elias M, Rosner I, Kaly L, et al. Effects of Tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and Adipokine levels in patients with rheumatoid arthritis. Int J Mol Sci 2019;20:18.

Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018;23:943-7.

Marano JG, Vaglio S, Pupella S, Facco G. Convalescent plasma: New evidence for an old therapeutic tool? Blood Transfus 2016;14:152-7.

Eickmann M, Gravemann U, Handke W, Tolksdorf F, Reichenberg S, Müller TH, et al. Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively. Transfusion 2018;58:2202-7.

Mora-Rillo M, Arsuaga M, Ramírez-Olivencia G, de la Calle F, Borobia AM, Sánchez-Seco P, et al. La Paz-Carlos III university hospital isolation unit, acute respiratory distress syndrome after convalescent plasma use: Treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med 2015;3:554-62.

Benson AB, Moss M, Silliman CC. Transfusion-related acute lung injury (TRALI): A clinical review with emphasis on the critically ill. Br J Haematol 2009;147:431-43.

Halstead SB. Dengue antibody-dependent enhancement: Knowns and unknowns. Microbiol Spectr 2014;2:AID-0022-2014.

South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol 2020;318:H1084-90.

Hoffmann M, Kleine-Wever H, Kruger N, Muller M, Drotsten C, Pholhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry in target cells. Cell 2020;181:1-10.

Huang F, Guo J, Zou Z, Liu J, Cao B, Zhang S, et al. Angiotensin II plasma levels are linked to disease severity and predict fataloutcomes in H7N9-infected patients. Nat Commun 2014;5:3595-602.

Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-convertingenzyme 2 protects from severe acute lung failure. Nature 2005;436:112-6.

Chihrin S, Loutfy MR. Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome. Expert Rev Anti Infect Ther 2005;3:251-62.

Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel Covid-19 a systematic review of current evidence. Ecancermedicalscience 2020;14:1022.

Horowitz RI, Freeman PR, Bruzzesec J. Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases. Respir Med Case Rep 2020;30:101063.

Available from: https://www.firstpost.com/health/medical-team-in-bangladesh-suggests-combination-of-ivermectin-and-doxycycline-for-covid-19-treatment-8380171.html